Hutchison China Meditech Ltd - China-based biopharmaceutical company - Initiates a phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors, in patients with advanced intrahepatic cholangiocarcinoma, which is a type of liver cancer. The clinical study is a single-arm, multi-center, open-label study, evaluating the efficacy, safety and pharmacokinetics of HMPL-453 in patients with advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptors fusion that had failed at least one line of systemic therapy. The primary outcome measure is objective response rate. Secondary outcome evaluations include preliminary efficacy measures, such as disease control rate, time to response, duration of response, progression-free survival, and overall survival.
Current stock price: 508.00 pence
Year-to-date change: up 27%
By Evelina Grecenko; firstname.lastname@example.org
Copyright 2020 Alliance News Limited. All Rights Reserved.